The Efficacy and Safety of Minocycline‐Containing Quadruple Therapies Against Helicobacter pylori Infection: A Retrospective Cohort Study

Abstract

Xiao-Bei Si,1,2 Ling-Yun Zhang,2 Shuo Yang,3 Xiao-Lu Chen,2 Yan-Yan Shi,4 Yu Lan,2 Shi-Gang Ding1 1Department of Gastroenterology, Peking University Third Hospital, Beijing, People’s Republic of China; 2Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, People’s Republic of China; 3Department of Pharmacy, Beijing Jishuitan Hospital, Capital Medical University, Beijing, People’s Republic of China; 4Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, People’s Republic of ChinaCorrespondence: Shi-Gang Ding, Department of Gastroenterology, Peking University Third Hospital, Beijing, People’s Republic of China, Email [email protected] Yu Lan, Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, People’s Republic of China, Email [email protected]: Minocycline, a derivative of tetracycline, has anti-Helicobacter pylori (H. pylori) properties and can be used to treat H. pylori infection. However, only a few randomized controlled trials (RCTs) have investigated the efficacy of minocycline-containing quadruple therapy (MCQT) in treating H. pylori infection. This study aimed to determine the efficacy and safety of MCQT and investigate the factors influencing both aspects.Methods: This was a retrospective cohort study. Patients diagnosed with H. pylori infection between January 1, 2022, and July 31, 2023 at. The primary outcome was the eradication rate of H. pylori, and the secondary outcome was the number and type of adverse events.Results: A total of 828 patients were included in this study. The overall H. pylori eradication rate among the included patients at 95% confidence interval (CI) (Range 0.864 to 0.907) was 88.53%. The H. pylori eradication rate for patients who received MCQT regimen as the primary therapy was 92.28% (95% CI: 0.901– 0.945), significantly higher than that of patients who received MCQT as rescue therapy (80.81%; 95% CI: 0.761– 0.855, P= 0.003). Adverse events, including dizziness, abdominal distension, diarrhea, nausea, abdominal discomfort, constipation, headache, rash, sleep disorder, palpitation, backache, and anorexia, occurred in 185 (22.34%) patients, with dizziness being the most common (75/828, 9.06%). Compliance with MCQT therapy was an independent factor influencing H. pylori eradication in patients receiving MCQT as a primary therapy. Compliance and presence or absence of H. pylori infection symptoms at the time of screening were independent factors influencing H. Pylori eradication in patients receiving MCQT as rescue therapy. Factors that influenced the occurrence of adverse events included reasons for H. pylori infection screening, residence, treatment compliance, and the use of acid-suppressant regimens.Conclusion: MCQT regimens were effective in H. pylori infection eradication, and the treatment resulted only in fewer adverse events when used as primary or rescue therapies for H. pylori infection treatment. Future prospective studies with larger sample sizes and more comprehensive data are needed to validate our findings.Keywords: Helicobacter pylori, minocycline, cohort study

Keywords

• helicobacter pylori
• minocycline
• cohort study